

# Functionality and protective effect of S-layer proteins in microencapsulated freeze-dried probiotic *Levilactobacillus brevis* strains

DOI: 10.15567/mljekarstvo.2024.0304

Nina Čuljak, Andreja Leboš Pavunc\*, Kristina Dučkić, Katarina Butorac, Martina Banić, Jasna Novak, Jagoda Šušković, Blaženka Kos

University of Zagreb Faculty of Food Technology and Biotechnology, Laboratory for Antibiotic, Enzyme, Probiotic and Starter Culture Technologies, Pierottijeva 6, 10000 Zagreb, Croatia

Received: 20.02.2024. Accepted: 15.06.2024.

\*Corresponding author: andreja.lebos.pavunc@pbf.unizg.hr

## Abstract

The presence of surface (S)-layer proteins as a rare property of lactic acid bacteria plays an important role in the expression of the probiotic properties of the producer strain and protects the cells from unfavourable environmental conditions. Therefore, the aim of this work was to evaluate the role of S-layer proteins of four *Levilactobacillus brevis* MB1, MB2, MB13, and MB20 strains, previously isolated from human milk. The results showed better survival under simulated gastrointestinal tract (GIT) conditions and better adhesion to Caco-2 cells, achieved when S-proteins were present on the surface of the examined probiotic *Levilactobacillus brevis* strains. Free cells and cells microencapsulated in alginate, with or without galactooligosaccharides (GOS) and fructooligosaccharides (FOS), survived in high numbers during freeze-drying and one-month storage at 4 °C, as well as during exposure to simulated GIT conditions ( $>10^8$  CFU/g), thus fulfilling the primary technological criterion for the selection of probiotic strains. Higher survival of freeze-drying of encapsulated cells than free cells, can be attributed to the protective effect of alginate, GOS and FOS as prebiotic agents. However, GOS was more protective than FOS in maintaining the viability of microencapsulated *Levilactobacillus brevis* MB1, MB2, MB13 and MB20 cells in alginate during storage and under the harsh conditions of GIT and freeze-drying.

**Keywords:** *Levilactobacillus brevis*; S-layer proteins; probiotic; functional properties; microencapsulation

## Introduction

Lactic acid bacteria (LAB) strains from human milk are capable of producing potential therapeutic biomolecules. Previously isolated four strains of *Levilactobacillus brevis* MB1, MB2, MB13, and MB20, are capable of producing S-proteins, as demonstrated after proteomic analysis and trypsinization followed by liquid chromatography-mass spectrometry (LC-MS) and Mascot search (Banić et al., 2022). Surface (S)-layer proteins (S-proteins) are two-dimensional, paracrystalline, monomolecular crystalline structures of surface (glyco)proteins that cover the cell surface of hundreds of different species of almost all taxonomic groups of Gram-positive and Gram-negative bacteria and archaea in the form of a layer (S-layer) (Assandri et al., 2023). As the outermost layer covering the surface of the cell, the S-protein layer is in direct contact with its microenvironment, and the role of S-proteins can be studied from two different approaches - their role in the adhesion of bacteria to various surfaces and substrates and their role as a mechanical barrier in a harmful environment (Gerbino et al., 2015). The expression of S-proteins in probiotic bacteria is a rare but desirable trait, as it has been shown to play an important role in the expression of the probiotic properties of the producer strain. It protects the cells from unfavourable environmental conditions, but also influences many cell surface properties, including surface recognition, auto aggregation and co-aggregation, and adhesion to various epithelial and subepithelial structures (Banić et al., 2018; Butorac et al., 2020; Novak et al., 2021; Banić et al., 2022). Probiotics not only have great potential for broad biotechnological application (Novak et al., 2022), but also have many health benefits, such as prevention of gastrointestinal tract (GIT) diseases and allergies, antidepressant, anticancer and immunomodulatory activities (Zommiti et al., 2020). However, their activity is impaired by the methods of powder production, storage and unfavourable conditions in the digestive tract (Vivek et al., 2023). One of the techniques for administering probiotics is microencapsulation in protective capsules that form a physical barrier to improve the survival and bioavailability of the probiotics (Razavi et al., 2021). Alginate is widely used as a carrier for the delivery of probiotics in microcapsules and has attracted attention due to its excellent physicochemical and mechanical properties, including simple structure, simple raw materials, low toxicity, mild processing, and easy matrix formation around the bacteria (Wang et al., 2022). Furthermore, in order to prolong the survival time of the encapsulated probiotics during storage and in the human GIT, prebiotic substrates that are indigestible or only partially digestible in the GIT can be added

to stimulate the growth of the microbiota and probiotics in the human gut (Misra et al., 2022). There are numerous studies that report microencapsulation of probiotics in dairy products. For instance, Phoem et al. (2019) encapsulated *L. plantarum* TISTR1465 with Eleutherin Americana oligosaccharide extract using the extrusion technique demonstrated to be more effective than the free cells after exposure to the GIT and refrigerated storage in yoghurt. Also, Kavas et al. (2022) determined that administration of microencapsulated probiotic culture mixture (*Lactocaseibacillus casei* + *Bifidobacterium longum*) in white goat cheese production had a positive effect on the amount of unsaturated fatty acids. Although microencapsulation of probiotics provides higher viability and stability during the storage and consumption of dairy products (El Kadri et al., 2018), it can alter textural and rheological properties (Li et al., 2020; Ningtyas et al., 2019). Therefore, it is important to choose appropriate encapsulation technique and coating materials for maintaining viability and food properties.

The aim of this work was therefore to investigate the role of S-proteins in enhancing the probiotic potential of the producer strains, particularly in relation to the better ability to survive simulated GIT conditions and better adhesion to Caco-2 cells, but also the protective effect of microencapsulation of *L. brevis* strains in alginate, with and without the addition of the prebiotic substrates fructooligosaccharides (FOS) and galactooligosaccharides (GOS), under unfavourable conditions during freeze-drying, passage through simulated GIT conditions and effect on viable cells stability during one-month storage.

## Materials and methods

### Bacterial strains and culture conditions

The S-layer-producing strains *Levilactobacillus brevis* MB1, MB2, MB13 and MB20, isolated from human milk, were maintained frozen at -80 °C in MRS (de Man Rogosa Sharpe; Difco, Detroit, MI, USA) broth supplemented with 15 % (by volume) glycerol (Alkaloid, Skopje, North Macedonia). All strains used in this study are part of the Culture collection of the Laboratory for Antibiotic, Enzyme, Probiotic and Starter Cultures Technology, University of Zagreb Faculty of Food Technology and Biotechnology. Prior to each experiment, all strains were sub cultured twice in a suitable medium under the growth conditions listed in Table 1.

**Table 1.** Bacterial strains used in this study

Bacterial strain	Cultivation conditions
<i>Levilactobacillus brevis</i> MB1	MRS broth, 37 °C, microaerophilic
<i>Levilactobacillus brevis</i> MB2	MRS broth, 37 °C, microaerophilic
<i>Levilactobacillus brevis</i> MB13	MRS broth, 37 °C, microaerophilic
<i>Levilactobacillus brevis</i> MB20	MRS broth, 37 °C, microaerophilic

\*microaerophilic conditions were created using Anaerocult A system (Merck, Darmstadt, Germany)

## Treatment of *Levilactobacillus brevis* cells with guanidine hydrochloride

In order to remove S-proteins present on the surface of *L. brevis* MB1, MB2, MB13 and MB20, cells were harvested after overnight incubation, washed, resuspended in 3 M guanidine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) and incubated for 1 h with shaking at room temperature. Cells were then washed in distilled water to remove residual guanidine hydrochloride thus obtaining S-layer-depleted *L. brevis* strains (S-). Untreated *L. brevis* cells (S+) were prepared for the experiments in the same way, except that distilled water was used instead of guanidine hydrochloride. To confirm S-layer removal from the treated bacterial cells, protein extracts were subjected to Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) following protocol by Barukčić Jurina et al. (2024). Electrophoretic separation of proteins was performed using a power-supply PowerPac HC™ (Biorad, Hercules, CA, USA) at a constant voltage of 150 V, along with the ProSieve QuadColor Protein Marker 4.6-315 kDa (Lonza, Morristown, NJ, USA).

## Survival of S-layer-producing *Levilactobacillus brevis* strains in simulated gastrointestinal tract (GIT) conditions

To study the survival of *L. brevis* strains MB1, MB2, MB13 and MB20 during incubation under simulated GIT conditions, simulated gastric and small intestinal juices were prepared as described by Kos et al. (2000). Simulated gastric juice was prepared by suspending pepsin (3 g/L; Sigma-Aldrich, Merck, St. Louis, MO, USA) in a sterile sodium chloride solution (0.5 %; Kemika, Zagreb, Croatia) and pH was adjusted with hydrochloric acid (Kemika, Zagreb, Croatia). Simulated small intestinal juice was prepared by suspending pancreatin (1 g/L; Fluka Biochemica, Buchs, Switzerland) and bile salts (1.5 g/L; Difco, Detroit, MI, USA). Overnight cultures of *L. brevis* strains were harvested by centrifugation, washed twice and resuspended in simulated gastric juice (pH = 2) and incubated for 2 h before cell viability was determined. After incubation in simulated gastric juice, the cells were harvested by centrifugation, resuspended in simulated small intestinal juice (pH = 8) and incubated for 4 h before cell viability was determined. The viable cell count was determined after 24 h of anaerobic incubation at 37 °C.

## In vitro adhesion of S-layer-producing *Levilactobacillus brevis* strains to Caco-2 cell line

*In vitro* adhesion of *L. brevis* strains MB1, MB2, MB13, and MB20 to the Caco-2 cell line was performed as previously described by Butorac et al. (2021), with modifications. In brief, Caco-2 monolayers were seeded in 24-well tissue culture plates (Falcon®, Durham, USA) until confluent monolayers

were obtained and then rinsed three times with phosphate-buffered saline (PBS, pH = 7.4). Subsequently, 1 mL of the prepared *L. brevis* bacterial suspension (approx. 10<sup>9</sup> CFU/mL) was added to each well and incubated for 1 h at 37 °C in an atmosphere of 5 % CO<sub>2</sub>. The monolayers were then washed three times with PBS to remove non-adherent bacterial cells. The total number of adhered bacterial cells in each well was counted after the Caco-2 cells were lysed with 0.05 % (by volume) Triton X-100 (AppliChem, Darmstadt, Germany) at 37 °C for 10 min. To determine the number of viable bacteria, adhered to the Caco-2 cells, appropriate dilutions in physiological solution were inoculated onto MRS agar plates and colony count was performed. Adhesion to the Caco-2 cell line was calculated using the following equation:


$$\Delta\log(\text{CFU/mL}) = \log(\text{CFU/mL})_{\text{before adhesion}} - \log(\text{CFU/mL})_{\text{after adhesion}}$$

## Microencapsulation of S-layer-producing *Levilactobacillus brevis* strains

Microencapsulation of *L. brevis* strains MB1, MB2, MB13, and MB20 was performed according to the procedure described in Butorac et al. (2021) with some modifications. Overnight *L. brevis* cultures were pelleted by centrifugation at 4200 rpm for 10 min, washed twice and suspended in 2 % (m/V) sodium alginate (Fluka, Buchs, Switzerland) and 2 % (m/V) sodium alginate with addition of prebiotic substrates, fructooligosaccharides (FOS; Sigma-Aldrich, St. Louis, MO, USA) or galactooligosaccharides (GOS; Biosynth, St. Gallen, Switzerland), at a concentration of 5 % (m/V). Using a syringe and a needle (23 G), the mixture of bacterial cells and alginate or alginate+FOS or alginate+GOS was gradually dripped into a 1 % calcium chloride solution (Gram-mol, Zagreb, Croatia) while stirring on a magnetic stirrer, forming microcapsules. The beads were left on a magnetic stirrer for 1 hour to solidify. They were then washed twice with saline and the number of microencapsulated cells after release from the microcapsules was determined after treatment with 2 % (m/V) Na-citrate (Kemika, Zagreb, Croatia) (Figure 1).

In addition, the microcapsules were suspended in 10 % (m/V) skimmed milk (Fluka, Buchs, Germany), frozen at -80 °C and freeze-dried in the Alpha 1-2 LD plus freeze dryer (Martin Christ, Osterode, Germany). The freeze-dried microencapsulated cells were examined for their viability after 1 month of storage at 4 °C, while the non-encapsulated (free) cells served as a control. Subsequently, the freeze-dried microencapsulated cells were exposed to simulated GIT conditions as described above.

The data obtained on the number of viable cells after freeze-dried, GIT transition and 1-month storage is expressed as cell mortality - a logarithmic reduction of colony forming units per gram of freeze-dried cell powder [ $\Delta\log(\text{CFU/g})$ ].



**Figure 1.** Schematic representation of the microencapsulation method (image created with BioRender.com)

## Statistical analysis

All experiments were repeated three times and the results were expressed as the mean of three independent values  $\pm$  standard deviation. Statistical significance was determined by one-way analysis of variance (ANOVA). Pairwise differences between group means were determined using Tukey's honestly significant difference test for post-analysis of variance pairwise comparisons (<https://www.statskingdom.com/index.html>, accessed on 11 February 2024) (Statistics Kingdom, 2017). Images were created using GraphPad Prism v.9.4.1 (GraphPad Software, USA). Differences between samples were considered significant at  $p < 0.05$ .

## Results and discussion

### *The role of S-layer proteins of Levilactobacillus brevis strains in simulated GIT conditions survival*

Cell surface proteins profiling of LAB strains isolated from human milk revealed the presence of S-proteins in four strains, manifested by a characteristic band of about 50 kDa after SDS-PAGE, and gene encoding for S-proteins production were detected after whole genome sequencing of *Levilactobacillus brevis* strains MB1, MB2, MB13, and MB20 (Accession No. SAMN22155538, SAMN22155539, SAMN22155540 and SAMN22155541, respectively; BioProject No. PRJNA388578). In addition, the expression of S-proteins, after trypsinization of the protein bands cut from the polyacrylamide gel, was also confirmed by LC-MS after Mascot search (Banić et al., 2022).

These four *L. brevis* strains were used in an experiment investigating the protective role of S-layer proteins in the

survival under unfavourable GIT conditions. This included a two-hour exposure to simulated gastric juice (pH = 2) followed by a four-hour exposure to simulated small intestinal juice (pH = 8). When comparing the viability of cells that were not treated with guanidine hydrochloride, a positive role of S-proteins was observed, as the number of live cells (CFU/mL) was significantly higher in untreated strains than in the same strains from which the S-layer was removed (Figure 2). S-proteins of *L. brevis* MB13 and MB20 strains had the greatest impact on survival in the GIT, as the strains without S-layer did not survive the harmful conditions of simulated small intestine juice. Our results are consistent with those of other researchers, such as Abramov et al. (2020) who demonstrated that *Lactobacillus crispatus* 2029 cells unable to produce Slp2 reduced the survival in simulated gastric and intestinal juices by 2–3 logs. According to previous results, *L. brevis* D6 strain, an S-protein producer, showed better ability to survive under simulated GIT conditions than the *L. plantarum* D13 without S-layer, which served as a negative control (Uroić et al., 2016), and as the  $\Delta\log(\text{CFU/mL})$  of the *L. brevis* SF9B strain with S-layer was significantly lower than that of the same strain but without S-layer (Banić et al., 2018).


### *The role of S-proteins in ability of Levilactobacillus brevis to adhere to Caco-2 cell line*

The ability to adhere to the host's intestinal surface is one of the main criteria in the selection of potential probiotic bacteria, as it leads to colonization and thus stimulation of the immune system as well as stimulation of the intestinal barrier and metabolic functions (Wang et al., 2022). In addition, probiotic bacteria have a potential protective role against enteropathogens through various mechanisms, which include the production of antimicrobial compounds,


competition for binding sites and the resulting reduction in the adhesion of pathogenic strains (Monteagudo-Mera et al., 2019). Therefore, the adhesion ability of *L. brevis* strains MB1, MB2, MB13 and MB20, which possess S-layer on their surface, as well as strains in which the S-layer was removed by chemical treatment with guanidine hydrochloride, was tested on Caco-2 cells, since they serve as an intestinal epithelial barrier model (Figure 3). The results showed a positive role of S-layer proteins in adhesion ability, as the  $\Delta\log(\text{CFU/mL})$  values of all tested *L. brevis* strains were higher when the cells were treated with guanidine hydrochloride, meaning that fewer *L. brevis* cells with the S-layer removed were able to bind to the Caco-2 cell line compared to the same strains expressing S-proteins on their surface. This effect was particularly evident in the *L. brevis* MB1 and MB20 strains, as the difference between the non-depleted and depleted strains was highest ( $p < 0.0001$ ). Our results are consistent with the evidence for the importance of S-proteins for the adhesion properties of the producer strain. Similar results were obtained by Klotz (2020), who demonstrated that S-layer deletion mutants of *Lactobacillus acidophilus* NCFM exhibited a reduced ability to bind to the Caco-2 cell line, as well as adhesion to extracellular matrices and mucin *in vitro*.

### Microencapsulation of S-layer-producing *Levilactobacillus brevis* strains in alginate, with the addition of FOS and GOS as prebiotics, and their role in survival under adverse conditions

In recent decades, modern and innovative microencapsulation methods have been developed, leading to the production of a wide range of functional probiotic microcapsules. Successful methods used in the microencapsulation of probiotics include various physical and chemical principles, such as spray drying, spray cooling, spray freeze drying, freeze drying, lyophilisation, electro spraying, layer-by-layer (LbL) method, fluidized bed drying, extrusion, vibrating nozzles technology, emulsification and coacervation (Pech-Canul et al., 2020). The extrusion technique is a popular method due to its simplicity, low cost on a small scale, easy handling and mild formulation conditions that ensure the survival of bacterial cell (Frakolaki et al., 2021). A hydrocolloid solution (e.g. alginate) is prepared, microorganisms (probiotics) are added and the cell suspension is pressed through a needle with gentle mixing into a solution with polyvalent cations (Figure 1). For microencapsulation in alginate polymer, a calcium chloride solution is usually used, in which calcium alginate beads are formed in which bacterial cells are enclosed. Concentration ranges of 1-2 % alginate and 0.05-1.5 M calcium chloride are common (Pech-Canul et al., 2020). In addition to the classic carriers, the addition of oligosaccharides such as  $\beta$ -glucan and FOS has been shown to improve the survival of probiotics. Prebiotics are not degraded by enzymes in the GIT, but can be utilised by bifidobacteria, LAB and other desirable bacterial species in the colon (Liao et al., 2019).




**Figure 2.** Viability of *Levilactobacillus brevis* MB1, MB2, MB13, and MB20 cells, with (S+) or without (S-) S-layer proteins, under simulated GIT conditions after incubation in simulated gastric juice (t = 2 h) and after incubation in simulated small intestine juice with direct transition (t = 4 h)



**Figure 3.** Adhesion of *Levilactobacillus brevis* strains MB1, MB2, MB13, and MB20, with (S+) or without (S-) S-layer proteins, to the Caco-2 cell line. Lower  $\Delta\log(\text{CFU/mL})$  values indicate better adhesive properties of the strains tested. \*Significantly different ( $*p < 0.05$ ,  $***p < 0.001$ ,  $****p < 0.0001$ )

In order to protect the LAB, producers of potential therapeutic biomolecules, and thus increase their probiotic potential, one of the objectives of this work was to carry out the microencapsulation of *L. brevis* strains in alginate, alginate with the addition of GOS and alginate with the addition of FOS by the extrusion method (Figure 4).


The efficacy of the microencapsulation process of strains producing S-proteins was also tested (Table 2). The efficiency of microencapsulation of strains in alginate with the addition of GOS was highest for all strains, except for strain MB1, for which there was no significant difference between the different compositions of microcapsules. According to previously published studies, the efficiency of microencapsulation by extrusion is between 89.2 % and 98.8 %, but results with a lower efficiency of 30.6 % to 45.5 % have also been published (How et al., 2022).



**Figure 4.** Microencapsulated *Levilactobacillus brevis* MB1 cells in alginate after dipping into a 1% calcium chloride solution (a) and freeze-dried capsules (b)

When probiotic preparations are administered orally, the conditions for their survival are harsh, so that the number of live probiotic bacteria decreases by  $10^6$  CFU/g preparation after only 5 min of incubation in simulated gastric juice (Dodoo et al., 2017). Many probiotics in commercial products belong to the genus *Lactobacillus* or *Bifidobacterium*, which are sensitive to unfavourable conditions in the stomach and intestines. Therefore, it is necessary to develop effective methods to improve the stability of probiotics in food and during their passage through the human GIT. Microencapsulation has been proposed as an effective method to protect probiotics from degradation under such unfavourable conditions (Sipailiene and Petraityte, 2018; Razavi et al., 2021). Probiotic delivery system should be designed to release the probiotics in the colon so that they can have a beneficial impact on the health of the host. In addition, probiotics should be able to adhere to and colonize the colonic mucosa, otherwise they will not survive to have positive effects on host health (Bosnea et al., 2017; Wang et al., 2022). An effective microencapsulation system should maintain the stability of the probiotics during storage, protect them in the upper part of the GIT and release them in the colon so that the probiotics can adhere to and colonize the gut (Anselmo et al., 2016; Cassani et al., 2020).

Freeze-drying is one of the most suitable methods for drying sensitive materials such as microorganisms, and it also has good dissolution/suspension properties of dried materials. Despite the advantages of freeze-drying, there might be a significant loss of probiotic survival during the drying process and storage period due to changes in the membrane lipids



**Figure 5.** Cell mortality [ $\Delta\log(\text{CFU/g})$ ] of free and microencapsulated *Levilactobacillus brevis* MB1, MB2, MB13, and MB20 cells in alginate, with or without addition of FOS (fructooligosaccharides) or GOS (galactooligosaccharides), after freeze-drying

and sensitive proteins of the bacterial cell caused by the low temperatures during the freezing phase, the formation of ice crystals and the evaporation rate of these crystals (Gul and Atalar, 2018). Skim milk was used as a lyoprotective agent in the freeze-drying of microcapsule samples containing probiotics, as it has also been shown in our previous research to stabilize the cell membrane and provide the cell with a protective layer (Butorac et al., 2021). The results (Figure 5) show that cell mortality [ $\Delta\log(\text{CFU/g})$ ] was significantly lower for MB1 and MB20 strains compared to alginate/alginate+FOS/free cells. Free cells of the MB2 strain had a significantly higher cell mortality rate than microencapsulated cells. As for MB13 strain, cell mortality was significantly lower with alginate+GOS and alginate+FOS compared to alginate alone and free cells. Overall, microencapsulation of *L. brevis* strains in alginate with the addition of GOS proved to be the best method for protecting cells during freeze-drying for all strains tested. Microencapsulation of the *Limosilactobacillus fermentum* D12 strain in alginate significantly improved the ability of the tested strain to survive the freeze-drying process as well as survival under simulated GIT conditions compared to the non-encapsulated strain (Butorac et al., 2021). Raddatz et al. (2020) demonstrated that other microencapsulation methods (emulsification) with the addition of various prebiotic substrates (hi-maize, inulin, and rice bran) can also improve survival in the freeze-drying process, but also under other unfavourable conditions.

After oral administration, probiotic bacteria are confronted with extremely low pH values in the stomach, and in the colon

**Table 2.** Efficiency of the microencapsulation (encapsulation yield, EY) of *Levilactobacillus brevis* MB1, MB2, MB13, and MB20 cells in alginate, with or without addition of fructooligosaccharides (FOS) or galactooligosaccharides (GOS)

STRAIN	alginate	alginate + FOS	alginate + GOS
MB1	65.25±5.85 <sup>a</sup>	79.96±8.75 <sup>a</sup>	73.30±5.71 <sup>a</sup>
MB2	70.88±4.56 <sup>b</sup>	64.85±9.77 <sup>b</sup>	85.85±7.78 <sup>a</sup>
MB13	58.39±3.99 <sup>b</sup>	83.11±5.40 <sup>a</sup>	86.97±9.92 <sup>a</sup>
MB20	69.60±7.10 <sup>b</sup>	65.78±3.47 <sup>b</sup>	85.64±5.27 <sup>a</sup>

Different letters in superscript indicate statistically significant difference among the data across the same row ( $p < 0.05$ )


there is competition for nutrients and adhesion sites on the mucosa, the action of the host's immune system, all of which can affect the concentration of live microorganisms *in situ* (Butorac et al., 2021). Therefore, the ability of freeze-dried microencapsulated S-protein-producing *L. brevis* strains to survive simulated GIT conditions was evaluated (Figure 6). Microencapsulation in alginate with the addition of GOS proved to be the best method to protect the cells of all tested *L. brevis* strains, as a statistically significant difference was found when examining cell mortality [ $\Delta\log(\text{CFU/g})$ ], compared to other microencapsulation methods as well as to free cells. Our results confirmed that microencapsulation techniques improve survival in the GIT, thus contributing to probiotic delivery to the target site of action, which was confirmed by other authors (Butorac et al., 2021; Pupa et al., 2021; Barajas-Alvarez et al., 2022).

The survival of lyophilized microencapsulated *L. brevis* strains stored at 4 °C for one month was also monitored. The results show that cell mortality [ $\Delta\log(\text{CFU/g})$ ] after one month of storage is significantly lower when the *L. brevis* MB1 and MB2 cells are microencapsulated in alginate with the addition of GOS, compared to alginate with or without the addition of FOS and the non-encapsulated free cells (Figure 7). As for the other two strains, *L. brevis* MB13 and MB20, the addition of GOS was also successful, but the addition of FOS had a similar positive effect on maintaining cell viability.


Since potential prebiotic substrates were used in the microencapsulation process, these matrices, in addition to their protective effect, also play an important role as potential carbon and energy sources for the intestinal microbiota and for the probiotic strains in the microcapsules themselves, which are indigestible and are only metabolized by the metabolic activity of the microbiota in the intestinal tract, producing short-chain fatty acids whose beneficial effects on host health have been demonstrated in numerous studies (Markowiak-Kopeć and Ślizewska, 2020; Robles-Vera et al., 2020; Cheng et al., 2022).

## Conclusions

The S-proteins located on the surface of *L. brevis* strains MB1, MB2, MB13 and MB20 showed a protective role in survival under simulated GIT conditions and positive influence on adhesion to the Caco-2 epithelial cells, thus demonstrating an additional competitive advantage of S-protein-producing bacteria in the selection of probiotic strains. From the results of the encapsulated and free cells of the tested strains of *L. brevis* after freeze-drying and passing through simulated GIT conditions, it can be concluded that the final number of live cells in all samples was above  $10^8$  CFU/g, so that the freeze-dried preparations of both free and encapsulated probiotic cells met the demanding technological criteria for achieving a probiotic effect ( $> 10^8$  CFU/g). The results of a higher number of encapsulated cells surviving freeze-drying than free cells can be attributed to the protective effect of the alginate, GOS and FOS as protective and prebiotic agents.



**Figure 6.** Cell mortality [ $\Delta\log(\text{CFU/g})$ ] of free and microencapsulated *Levilactobacillus brevis* MB1, MB2, MB13, and MB20 cells in alginate, with or without addition of FOS (fructooligosaccharides) or GOS (galactooligosaccharides), after exposure to simulated GIT conditions



**Figure 7.** Cell mortality [ $\Delta\log(\text{CFU/g})$ ] of free and microencapsulated *Levilactobacillus brevis* MB1, MB2, MB13, and MB20 cells in alginate, with or without addition of FOS (fructooligosaccharides) or GOS (galactooligosaccharides), after one month of storage

## Acknowledgements

The authors acknowledge associate professor Ksenija Durgo (University of Zagreb, Faculty of Food Technology and Biotechnology, Laboratory for Biology and Microbial Genetics) who provided Caco-2 cells for the adhesion experiment.

## Funding

This work was funded by the Croatian Science Foundation through the projects IP-2014-09-7009 and IP-2019-04-2237. The authors also acknowledge the financial support from the University of Zagreb, Croatia. The authors are also grateful for the equipment provided with financial support from the project "Bioprospecting of the Adriatic Sea" (KK.01.1.1.01.0002), granted to the Scientific Centre of Excellence for Marine Bioprospecting (BioProCro) at the Ruđer Bošković Institute, Zagreb, Croatia. Also, PhD student Nina Čuljak was a recipient of FEMS Research and Training Grant (FEMS-GO-2021-034) for early career scientists.

# Mikroinkapsulacija probiotičkih sojeva *Levilactobacillus brevis* s površinskim S-proteinima za poboljšanu zaštitu tijekom primjene i liofilizacije

## Sažetak

Prisutnost površinskog (*engl. surface, S*) sloja rijetko je svojstvo bakterija mliječne kiseline koje ima važnu ulogu u izražavanju probiotičkih svojstava sojeva producenata te štiti stanice od nepovoljnih uvjeta okoline. Stoga je cilj ovog rada bio ispitati ulogu S-sloja četiriju *Levilactobacillus brevis* MB1, MB2, MB13 i MB20 sojeva, prethodno izoliranih iz majčinog mlijeka. Rezultati su pokazali bolje preživljavanje ispitivanih *Levilactobacillus brevis* sojeva u simuliranim uvjetima gastrointestinalnog trakta (GIT) te bolju adheziju na Caco-2 stanice kada su S-proteini prisutni na površini stanica ispitivanih sojeva producenata. Slobodne stanice i stanice mikroinkapsulirane u alginatu, s ili bez galaktooligosaharida (GOS) i fruktooligosaharida (FOS), su preživjele u velikom broju nakon liofilizacije i jednomjesečnog skladištenja, kao i tijekom izlaganja simuliranim uvjetima GIT-a ( $> 10^8$  CFU/g), čime je ispunjen primarni tehnološki kriterij za odabir probiotičkih sojeva. Veće preživljavanje liofilizacije mikroinkapsuliranih stanica u odnosu na slobodne stanice može se pripisati zaštitnom učinku alginata, GOS-a i FOS-a kao prebiotičkih supstrata. Međutim, dodatak GOS-a se pokazao učinkovitijim u odnosu na FOS u održavanju vijabilnosti mikroinkapsuliranih stanica *Levilactobacillus brevis* MB1, MB2, MB13 i MB20 sojeva tijekom skladištenja i pod teškim uvjetima GIT-a i liofilizacije.

**Ključne riječi:** *Levilactobacillus brevis*; S-sloj; probiotik; funkcionalna svojstva; mikroinkapsulacija

## References

1. Abramov, V.M., Kosarev, I.V., Pripudnevich, T.V., Machulin, A.V., Khlebnikov, V.S., Pchelintsev, S.Y., Vasilenko, R.N., Sakulin, V.K., Suzina, N.E., Chikileva, I.O., Derysheva, E.I., Melnikov, V.G., Nikonov, I.N., Samoilenko, V.A., Svetoch, E.E., Sukhikh, G.T., Uversky, V.N., Karlyshev, A. V. (2020): S-layer protein 2 of *Lactobacillus crispatus* 2029, its structural and immunomodulatory characteristics and roles in protective potential of the whole bacteria against foodborne pathogens. *International Journal of Biological Macromolecules* 150, 400-412. <https://doi.org/10.1016/j.ijbiomac.2020.02.065>
2. Anselmo, A.C., McHugh, K.J., Webster, J., Langer, R., Jaklenec, A. (2016): Layer-by-layer encapsulation of probiotics for delivery to the microbiome. *Advanced Materials* 28 (43), 9486-9490. <https://doi.org/10.1002/adma.201603270>
3. Assandri, M.H., Malamud, M., Trejo, F.M., de los A Serradell, M. (2023): S-layer proteins as immune players: tales from pathogenic and non-pathogenic bacteria. *Current Research in Microbial Sciences* 4, 100187. <https://doi.org/10.1016/j.crmicr.2023.100187>
4. Banić, M., Butorac, K., Čuljak, N., Leboš Pavunc, A., Novak, J., Bellich, B., Kazazić, S., Kazazić, S., Cescutti, P., Šušković, J., Zucko, J., Kos, B. (2022): The human milk microbiota produces potential therapeutic biomolecules and shapes the Intestinal microbiota of infants. *International Journal of Molecular Sciences* 23 (22), 14382. <https://doi.org/10.3390/ijms232214382>
5. Banić, M., Uroić, K., Leboš Pavunc, A., Novak, J., Zorić, K., Durgo, K., Petković, H., Jamnik, P., Kazazić, S., Kazazić, S., Radović, S., Scalabrin, S., Hyn-nen, U., Šušković, J., Kos, B. (2018): Characterization of S-layer proteins of potential probiotic starter culture *Lactobacillus brevis* SF9B isolated from sauerkraut. *LWT-Food Science and Technology* 93, 257-267. <https://doi.org/10.1016/j.lwt.2018.03.054>
6. Barajas-Alvarez, P., Gonzalez-Avila, M., Espinosa-Andrews, H. (2022): Microencapsulation of *Lactobacillus rhamnosus* HN001 by spray drying and its evaluation under gastrointestinal and storage conditions. *LWT* 153, 112485. <https://doi.org/10.1016/j.lwt.2021.112485>



7. Barukčić Jurina, I., Blažević, I., Jurina, T., Leboš Pavunc, A., Božanić, R., Lisak Jakopović, K. (2024): Evaluation of heat-induced changes and 5-hydroxymethylfurfural formation in mare milk - a comparative study to cow milk. *Mljekarstvo* 74 (2), 89-105.  
<https://doi.org/10.15567/mljekarstvo.2024.0201>
8. Bosnea, L.A., Moschakis, T., Biliaderis, C.G. (2017): Microencapsulated cells of *Lactobacillus paracasei* subsp. *paracasei* in biopolymer complex coacervates and their function in a yogurt matrix. *Food and Function* 8 (2), 554-562.  
<https://doi.org/10.1039/C6FO01019A>
9. Butorac, K., Banić, M., Novak, J., Leboš Pavunc, A., Uroić, K., Durgo, K., Oršolić, N., Kukolj, M., Radović, S., Scalabrin, S., Žučko, J., Starčević, A., Šušković, J., Kos, B. (2020): The functional capacity of plantaricin-producing *Lactobacillus plantarum* SF9C and S-layer-carrying *Lactobacillus brevis* SF9B to withstand gastrointestinal transit. *Microbial Cell Factories* 19, 1-16.  
<https://doi.org/10.1186/s12934-020-01365-6>
10. Butorac, K., Novak, J., Bellich, B., Terán, L.C., Banić, M., Leboš Pavunc, A., Zjalić, S., Cescutti, P., Šušković, J., Kos, B. (2021): Lyophilized alginate-based microspheres containing *Lactobacillus fermentum* D12, an exopolysaccharides producer, contribute to the strain's functionality *in vitro*. *Microbial Cell Factories* 20, 1-17.  
<https://doi.org/10.1186/s12934-021-01575-6>
11. Cassani, L., Gomez-Zavaglia, A., Simal-Gandara, J. (2020): Technological strategies ensuring the safe arrival of beneficial microorganisms to the gut: From food processing and storage to their passage through the gastrointestinal tract. *Food Research International* 129, 108852.  
<https://doi.org/10.1016/j.foodres.2019.108852>
12. Cheng, Y., Liu, J., Ling, Z. (2022): Short-chain fatty acids-producing probiotics: A novel source of psychobiotics. *Critical reviews in food science and nutrition* 62 (28), 7929-7959.  
<https://doi.org/10.1080/10408398.2021.1920884>
13. Dodo, C.C., Wang, J., Basit, A.W., Stapleton, P., Gaisford, S. (2017): Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation. *International Journal of Pharmaceutics* 530 (1-2), 224-229.  
<https://doi.org/10.1016/j.ijpharm.2017.07.068>
14. El Kadri, H., Lalou, S., Mantzouridou, F., Gkatzionis, K. (2018): Utilisation of water-in-oil-water (W1/O/W2) double emulsion in a set-type yogurt model for the delivery of probiotic *Lactobacillus paracasei*. *Food Research International* 107, 325-336.  
<https://doi.org/10.1016/j.foodres.2018.02.049>
15. Frakolaki, G., Giannou, V., Kekos, D., Tzia, C. (2021): A review of the microencapsulation techniques for the incorporation of probiotic bacteria in functional foods. *Critical reviews in food science and nutrition* 61(9), 1515-1536.  
<https://doi.org/10.1080/10408398.2020.1761773>
16. Gerbino, E., Carasi, P., Mobili, P., Serradell, M.A., Gómez-Zavaglia, A. (2015): Role of S-layer proteins in bacteria. *World Journal of Microbiology and Biotechnology* 31, 1877-1887.  
<https://doi.org/10.1007/s11274-015-1952-9>
17. Gul, O., Atalar, I. (2019): Different stress tolerance of spray and freeze dried *Lactobacillus casei* Shirota microcapsules with different encapsulating agents. *Food Science and Biotechnology* 28, 807-816.  
<https://doi.org/10.1007/s10068-018-0507-x>
18. How, Y.H., Lai, K.W., Pui, L.P., In, L.L.A. (2022): Co-extrusion and extrusion microencapsulation: Effect on microencapsulation efficiency, survivability through gastrointestinal digestion and storage. *Journal of Food Process Engineering* 45 (3), e13985.  
<https://doi.org/10.1111/jfpe.13985>
19. Kavas, N., Kavas, G., Kinik, Ö., Ateş, M., Şatır, G., Kaplan, M. (2022): Fatty acids and free amino acid composition of synbiotic goat cheese with free and encapsulated probiotics. *Mljekarstvo* 72 (4), 226-236.  
<https://doi.org/10.15567/mljekarstvo.2022.0404>

20. Klotz, C., Goh, Y.J., O'Flaherty, S., Barrangou, R. (2020): S-layer associated proteins contribute to the adhesive and immunomodulatory properties of *Lactobacillus acidophilus* NCFM. *BMC Microbiology* 20, 1-13.  
<https://doi.org/10.1186/s12866-020-01908-2>
21. Kos, B., Šušković, J., Goreta, J., Matošić, S. (2000): Effect of protectors on the viability of *Lactobacillus acidophilus* M92 in simulated gastrointestinal conditions. *Food Technology and Biotechnology* 38 (2), 121-127.
22. Li, H., Zhang, T., Li, C., Zheng, S., Li, H., Yu, J. (2020): Development of a microencapsulated symbiotic product and its application in yoghurt. *LWT - Food Sci. Technol.* 122, 109033.  
<https://doi.org/10.1016/j.lwt.2020.109033>
23. Liao, N., Luo, B.L., Gao, J., Li, X.J., Zhao, Z.X., Zhang, Y., Ni, Y., Tian, F.W. (2019): Oligosaccharides as co-encapsulating agents: Effect on oral *Lactobacillus fermentum* survival in a simulated gastrointestinal tract. *Biotechnology Letters* 41, 263-272.  
<https://doi.org/10.1007/s10529-018-02634-6>
24. Markowiak-Kopeć, P., Ślizewska, K. (2020): The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. *Nutrients* 12 (4), 1107.  
<https://doi.org/10.3390/nu12041107>
25. Misra, S., Pandey, P., Dalbhagat, C.G., Mishra, H.N. (2022): Emerging technologies and coating materials for improved probiotication in food products: A review. *Food and Bioprocess Technology* 15 (5), 998-1039.  
<https://doi.org/10.1007/s11947-021-02753-5>
26. Monteagudo-Mera, A., Rastall, R.A., Gibson, G.R., Charalampopoulos, D., Chatzifragkou, A. (2019): Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. *Applied Microbiology and Biotechnology* 103, 6463-6472.  
<https://doi.org/10.1007/s00253-019-09978-7>
27. Nactyas, D.W., Bhandari, B., Bansal, N., Prakash, S. (2019): The viability of probiotic *Lactobacillus rhamnosus* (non-encapsulated and encapsulated) in functional reduced-fat cream cheese and its textural properties during storage. *Food Control* (100), 8-16.  
<https://doi.org/10.1016/j.foodcont.2018.12.048>
28. Novak, J., Leboš Pavunc, A., Butorac, K., Banić, M., Čuljak, N., Rak, H., Blažević, M., Iveljić, A.M., Šušković, J., Kos, B. (2022): Caseinolytic proteases of *Lactobacillus* and *Lactococcus* strains isolated from fermented dairy products. *Mljekarstvo* 72 (1), 11-21.  
<https://doi.org/10.15567/mljekarstvo.2022.0102>
29. Novak, J., Butorac, K., Leboš Pavunc, A., Banić, M., Butorac, A., Lepur, A., Oršolić, N., Tonković, K., Bendelja, K., Čuljak, N., Lovrić, M., Šušković, J., Kos, B. (2021): A lactic acid bacteria consortium impacted the content of casein-derived biopeptides in dried fresh cheese. *Molecules* 27 (1), 160.  
<https://doi.org/10.3390/molecules27010160>
30. Pech-Canul, A.D.L.C., Ortega, D., García-Triana, A., González-Silva, N., Solis-Oviedo, R.L. (2020): A brief review of edible coating materials for the microencapsulation of probiotics. *Coatings* 10, 197.  
<https://doi.org/10.3390/coatings10030197>
31. Phoem, A.N., A. Mayiding, F. Saedeh, Permpoonpattana, P. (2019): Evaluation of *Lactobacillus plantarum* encapsulated with Eleutherine americana oligosaccharide extract as food additive in yoghurt. *Brazilian Journal of Microbiology* 50 (1), 237-246.  
<https://doi.org/10.1007/s42770-018-0017-2>
32. Pupa, P., Apiwatsiri, P., Sirichokchatchawan, W., Pirarat, N., Muangsin, N., Shah, A.A., Prapasarakul, N. (2021): The efficacy of three double-microencapsulation methods for preservation of probiotic bacteria. *Scientific Reports* 11, 13753.  
<https://doi.org/10.1038/s41598-021-93263-z>
33. Raddatz, G.C., Poletto, G., de Deus, C., Codevilla, C.F., Cichoski, A.J., Jacob-Lopes, E., Muller, E.I., Flores, E.M.M., Esmerino, E.A., de Menezes, C.R. (2020): Use of prebiotic sources to increase probiotic viability in pectin microparticles obtained by emulsification/internal gelation followed by freeze-drying. *Food Research International* 130, 108902.  
<https://doi.org/10.1016/j.foodres.2019.108902>

34. Razavi, S., Janfaza, S., Tasnim, N., Gibson, D.L., Hoorfar, M. (2021): Microencapsulating polymers for probiotics delivery systems: Preparation, characterization, and applications. *Food Hydrocolloids* 120, 106882.  
<https://doi.org/10.1016/j.foodhyd.2021.106882>
35. Robles-Vera, I., Toral, M., de la Visitación, N., Sánchez, M., Gómez-Guzmán, M., Romero, M., Yang, T., Izquierdo-García, J.L., Jiménez, R., Ruiz-Cabello, J., Guerra-Hernández, E., Raizada, M.K., Pérez-Vizcaino, F., Duarte, J. (2020): Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: Role of short-chain fatty acids. *Molecular nutrition & food research* 64 (6), 1900616.  
<https://doi.org/10.1002/mnfr.201900616>
36. Sipailiene, A., Petraityte, S. (2018): Encapsulation of probiotics: Proper selection of the probiotic strain and the influence of encapsulation technology and materials on the viability of encapsulated microorganisms. *Probiotics and Antimicrobial Proteins* 10, 1-10.  
<https://doi.org/10.1007/s12602-017-9347-x>
37. Statistics Kingdom (2017) One-way ANOVA Calculator and Tukey HSD, Statistics Kingdom: Website for Statistics calculators, Melbourne, Australia; 2017. Available from: <http://www.statskingdom.com>.
38. Uroić, K., Novak, J., Hynönen, U., Pietilä, T.E., Leboš Pavunc, A., Kant, R., Kos, B., Palva, A., Šušković, J. (2016): The role of S-layer in adhesive and immunomodulating properties of probiotic starter culture *Lactobacillus brevis* D6 isolated from artisanal smoked fresh cheese. *LWT-Food Science and Technology* 69, 623-632.  
<https://doi.org/10.1016/j.lwt.2016.02.013>
39. Vivek, K., Mishra, S., Pradhan, R.C., Nagarajan, M., Kumar, P.K., Singh, S.S., Manvi, D., Gowda, N.N. (2023): A comprehensive review on microencapsulation of probiotics: Technology, carriers and current trends. *Applied Food Research* 3 (1), 100248.  
<https://doi.org/10.1016/j.afres.2022.100248>
40. Wang, X., Gao, S., Yun, S., Zhang, M., Peng, L., Li, Y., Zhou, Y. (2022): Microencapsulating alginate-based polymers for probiotics delivery systems and their application. *Pharmaceuticals* 15 (5), 644.  
<https://doi.org/10.3390/ph15050644>
41. Zommiti, M., Feuilloley, M.G., Connil, N. (2020): Update of probiotics in human world: a nonstop source of benefactions till the end of time. *Microorganisms* 8 (12), 1907.  
<https://doi.org/10.3390/microorganisms8121907>